Medications Development Program Projects for Substance-Related Disorders (P01)

The summary for the Medications Development Program Projects for Substance-Related Disorders (P01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Medications Development Program Projects for Substance-Related Disorders (P01): With this Funding Opportunity Announcement (FOA), the National Institute on Drug Abuse (NIDA) solicits investigator-initiated program project (P01) grant applications that advance the discovery/development of new or existing therapeutics for the treatment of substance-related disorders (SRDs). Research projects in a program project grant must be closely related to a central theme that can be conducted effectively and efficiently through a coordinated collaborative approach using common resources, facilities, and instruments. Each research project within the P01 award must be supportable on its own merit. The scientific merit of each research project is assessed independently as well as within the context of the whole program. This initiative is designed to support an array of translational research programs, each comprised of at least three interrelated preclinical and/or clinical projects. As part of the program project, applicants are encouraged to develop synergistic collaborations with industry that enhance and strengthen the overall developmental potential of the proposed work. While the inclusion of an Administrative Core or other core is optional, it is expected that the PD/PI (or a multi-PI-coordinating group) will be responsible for the overall coordination of the program project and communication between components. Program projects can focus on the development of any sort of novel treatment strategies for cocaine, methamphetamine, cannabis, nicotine or opioid SRDs.

Federal Grant Title:	Medications Development Program Projects for Substance-Related Disorders (P01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DA-12-005
Type of Funding:	Grant
CFDA Numbers:	93.279
CFDA Descriptions:	Drug Abuse and Addiction Research Programs
Current Application Deadline:	Jul 29, 2011
Original Application Deadline:	Jul 29, 2011
Posted Date:	Mar 29, 2011
Creation Date:	Mar 29, 2011
Archive Date:	Aug 29, 2011
Total Program Funding:	$3,000,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Foreign (non-U.S.) components of U.S. Organizations are not allowed.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin (R01 Clinical...; • Dynamic and Adaptable Infrastructure for Drug Development and Outreach to Aid the Research...; • Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG...; • Single Source: National Longitudinal Study of Adolescent to Adult (Add) Health Wave VII (U...; • Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and P...; • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • Drug Abuse Aspects of Hiv/Aids and Other Infections; • Epidemiology of Drug Abuse
More Grants from the National Institutes of Health: • The Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Lab...; • The Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organizations ...; • NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed); • Single Source: Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Data Processing...; • NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed)